NCT02540707View on ClinicalTrials.gov

Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes

PHASE4CompletedINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

September 8, 2015

Primary Completion Date

August 26, 2020

Study Completion Date

August 26, 2020

Conditions
Overactive Bladder Syndrome
Interventions
DRUG

solifenacin

solifenacin 5 mg per day for 12 weeks

DRUG

mirabegron

mirabegron 25 mg per day for 12 weeks

Trial Locations (1)

100

Outpatient clinics, Department of Obs/Gyn, National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER

NCT02540707 - Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes | Biotech Hunter | Biotech Hunter